Effect of Febuxostat on vascular function in patients with hyperuricemia

Effect of Febuxostat on vascular function in patients with hyperuricemia - Effect of Febuxostat on vascular function in patients with hyperuricemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009468

Enrollment

Registered

2012-12-04

Start date

2012-12-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

Febuxostat Benzbromarone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hyperuricemia patients who meet the following criteria are enrolled; 1)Serum uric acid is greater than 8.0mg/dL with hypertension, ischemic heart disease, diabetes mellitus or metabolic syndrome, or serum uric acid is greater than 9.0mg/dL 2)Patients are required to the treatment of hyperuricemia 3)Age > 40 years 4)Patients agree to participate in this study.

Exclusion criteria

Exclusion criteria: The patients who meet the following criteria are excluded; 1)Patients will not take Febuxostat or Benzbromarone more than three months. 2)Frequent changes of concomitant medications are expected. 3)Patients with severe renal failure(eGFR<30 mL/min/1.73m2) and/ or on dialysis. 4)Pregnant woman 5)Patients have problems of severe allergic diseases on clinical course, or have a history of serious side effects and/or hypersensitivity to these drugs. 6)The physician judges that patients are inappropriate to attend this study.

Design outcomes

Primary

Measure	Time frame
Change of RHI measured by EndoPAT	—

Countries

Japan

Contacts

Public ContactSatoshi Ikeda

Nagasaki University Graduate School of Biomedical Sciences Department of Cardiovascular Medicine

uminchu-23-tomo@awa.bbiq.jp095-819-7288

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026